
"The incorporation and exclusion of technologies in SUS is based on the presence of scientific evidence demonstrating that the technology is at least as effective and safe as its counterparts already included in the scheme."
Tags:
Luciano Marques, president of Alcon Brazil, provides insights into recent investments and innovative initiatives aimed at strengthening Alcon’s relationships with its partners and customers in Brazil, and also documents the…
Maria del Pilar Muñoz, vice-president in charge of M&A and Sustainability at Eurofarma, one of the largest and most innovative pharmaceutical companies in Brazil with operations in 20 countries across…
Armando Correa Lopes Jr, managing director of Siemens Healthineers Brazil, provides insights into the main trends and challenges at the core of Brazil’s healthcare discussion and documents the contribution of…
See our Cookie Privacy Policy Here